Table 2. PFS and Association With Clinicopathologic Characteristics Using Cox Regression.
| Clinicopathologic variable | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Age at diagnosis | ||||
| Continuous | 1.00 (0.98-1.02) | .73 | NA | NA |
| ≥65 vs <65 y | 1.31 (0.81-2.13) | .27 | 1.87 (0.93-3.76) | .08 |
| Female vs male | 0.91 (0.60-1.40) | .68 | 1.13 (0.55-2.34) | .73 |
| Right- vs left-sided primary tumor | 1.21 (0.76-1.95) | .42 | 2.34 (1.07-5.13) | .03 |
| ECOG status 1 vs 0 | 1.43 (0.93-2.19) | .11 | 0.78 (0.37-1.65) | .52 |
| Metastasis site, involved vs noninvolveda | ||||
| Peritoneal | 1.58 (1.00-2.48) | .049 | 1.18 (0.54-2.60) | .68 |
| Liver | 4.98 (2.95-8.38) | <.001 | 7.00 (3.18-15.42) | <.001 |
| Lung | 1.04 (0.66-1.64) | .88 | 0.94 (0.40-2.21) | .89 |
| Lymph | 0.97 (0.63-1.47) | .88 | 1.02 (0.50-2.09) | .95 |
| Bone | 1.09 (0.54-2.17) | .81 | 0.58 (0.21-1.59) | .29 |
| Brain | 0.89 (0.28-2.82) | .84 | 1.95 (0.33-11.62) | .46 |
| Alteration vs no alteration | ||||
| APC b | 0.70 (0.41-1.21) | .20 | 0.59 (0.27-1.28) | .18 |
| RAS c | 1.47 (0.95-2.29) | .08 | 2.78 (1.19-6.47) | .02 |
| BRAF V600 | 0.48 (0.15-1.54) | .22 | 0.22 (0.04-1.31) | .10 |
| TP53 d | 0.91 (0.51-1.66) | .77 | 2.10 (0.84-5.24) | .11 |
| TMB (continuous)e | 0.99 (0.93-1.06) | .84 | 0.98 (0.88-1.08) | .63 |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; NA, not applicable; PFS, progression-free survival; TMB, tumor mutational burden.
a
Indicates at treatment.
b
Data were missing for 25 cases.
c
Includes KRAS and NRAS.
d
Data were missing for 24 cases.
e
Data were missing for 32 cases.